(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr21.60 | 8.25% | 19.84% |
| MEDISTIM (MEDI.OL) | kr157.50 | 2.76% | 24.73% |
| UCB (UCB.BR) | €153.75 | 0.89% | 2.67% |
| TUBIZE-FIN (TUB.BR) | €115.00 | 0.8% | 4.82% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
8.25% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.01. Meaning, the purchaser of the share is investing kr17.01 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Volatility
VISTIN PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.12%, a negative 0.05%, and a positive 1.42%.
VISTIN PHARMA’s highest amplitude of average volatility was 1.53% (last week), 1.04% (last month), and 1.42% (last quarter).
Moving Average
VISTIN PHARMA’s worth is below its 50-day moving average of kr21.97 and below its 200-day moving average of kr22.75.
More news about VISTIN PHARMA.
2. MEDISTIM (MEDI.OL)
2.76% Forward Dividend Yield and 24.73% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.6.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 28.12. Meaning, the purchaser of the share is investing kr28.12 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.73%.
More news about MEDISTIM.
3. UCB (UCB.BR)
0.89% Forward Dividend Yield and 2.67% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.22.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 126.02. Meaning, the purchaser of the share is investing €126.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.67%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UCB’s stock is considered to be oversold (<=20).
Moving Average
UCB’s worth is way above its 50-day moving average of €139.62 and way above its 200-day moving average of €105.76.
Yearly Top and Bottom Value
UCB’s stock is valued at €153.75 at 17:30 EST, below its 52-week high of €160.80 and way higher than its 52-week low of €65.40.
More news about UCB.
4. TUBIZE-FIN (TUB.BR)
0.8% Forward Dividend Yield and 4.82% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.03.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 56.65. Meaning, the purchaser of the share is investing €56.65 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.82%.
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €107.81 and way above its 200-day moving average of €86.61.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €115.00 at 17:30 EST, under its 52-week high of €124.80 and way above its 52-week low of €60.80.
Volume
Today’s last reported volume for TUBIZE-FIN is 11995 which is 31.98% below its average volume of 17637.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.11%, a positive 0.29%, and a positive 1.37%.
TUBIZE-FIN’s highest amplitude of average volatility was 4.75% (last week), 2.02% (last month), and 1.37% (last quarter).
More news about TUBIZE-FIN.
